Don’t shoot the messenger here - I am not advocating for a zero valuation but trying to explain how the finance folks look at valuations. With regard to IncellDX’s purchases I don’t believe the volume of product purchased would be material relative to the volume of current inventory.

The bigger issue is that uplisting is not what is going to drive long term value for the company - we need positive CD12 data - period.